ACAT2 and breast carcinoma: Taken together, our data suggest that despite the appropriate inhibition of ACAT2, the known effects of avasimibe on CYP450 activity enhanced fluvastatin metabolism and negated any benefit to dual targeting of the cholesterol synthesis pathway for breast cancer prevention.